administration of the Administration Act medical treatment): 1993 is also required. Contributes to the PBSP and The Endorsement: the risk assessment as delegated restrictive required. practices compliance officer. Restrictive Practice Recommended Consent and Potential Prescribing Person(s) Example Controls Endorsement Develops PBS practitioner: Refer to product Refer to the individual Consent: Person with the PBSP, contributes to the information but may Anti-psychotics product information but capacity to give risk assessment. include: generally should include: consent or their relative When there is no Medical practitioner/ or guardian. Extra-pyramidal relevant psychiatric Observation including • • psychiatrist (where the side effects that diagnosis, for example: monitoring for side If the person is restrictive practice is being include: effects (when resisting or objecting to Olanzapine • used to administer medical medication commenced, the medication, the Drooling Risperidone • treatment): Prescribes the increased, or ceased). consent of an Stiffness. Quetiapine medical treatment and • appointed guardian Awareness of toxicity • Sedation • contributes to the PBSP and Haloperidol. • with relevant powers symptoms. (causing risk assessment as required. Aripiprozale as per Section 32 of • Regular medical review. dysphagia, falls, • Community (where the Guardianship and Chlorpromazine • and pressure involved in the Administration Act Pericyazine. • areas). administration of the 1993 is also required. Agitation. • medical treatment): Endorsement: The Contributes to the PBSP and delegated restrictive the risk assessment as practices compliance required. officer.
administration of the medical treatment): Contributes to the PBSP and the risk assessment as required. Administration Act 1993 is also required. Endorsement: The delegated restrictive practices compliance officer. Restrictive Practice Example Potential Recommended Controls Prescribing Person(s) Consent and Endorsement Anti-psychotics When there is no relevant psychiatric diagnosis, for example: • Olanzapine • Risperidone • Quetiapine • Haloperidol. • Aripiprozale • Chlorpromazine • Pericyazine. Refer to product information but may include: • Extra-pyramidal side effects that include: Drooling Stiffness. • Sedation (causing dysphagia, falls, and pressure areas). • Agitation. Refer to the individual product information but generally should include: • Observation including monitoring for side effects (when medication commenced, increased, or ceased). • Awareness of toxicity symptoms. • Regular medical review. PBS practitioner: Develops the PBSP, contributes to the risk assessment. Medical practitioner/ psychiatrist (where the restrictive practice is being used to administer medical treatment): Prescribes the medical treatment and contributes to the PBSP and risk assessment as required. Community (where involved in the administration of the medical treatment): Contributes to the PBSP and the risk assessment as required. Consent: Person with capacity to give consent or their relative or guardian. If the person is resisting or objecting to the medication, the consent of an appointed guardian with relevant powers as per Section 32 of the Guardianship and Administration Act 1993 is also required. Endorsement: The delegated restrictive practices compliance officer.
restrictive-practices-reference-guide-south-australian-disability-sector.docx